Skip to main content

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH)

Baby being fed food

Study Overview: The primary objective of this study is to determine if a study medication called omalizumab (Xolair) alone or combined with oral immunotherapy may help people with multiple food allergies
Who Can Participate: Ages 1-55 years who have a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut, or walnut
Contact Information: Lauren Herlihy | (919) 962-4406 | Email- OUtMATCH@unc.edu
For more information, click here

OUtMATCH Video

Hypoallergenic Formula Study Baby smiling

Study Overview: This study is testing a new hypoallergenic formula in milk allergic infants and children. The new formula is a modification of the currently available formula Alimentum. The enzymes used in the new formula have been changed so that the new product can be Kosher and Halal.
Who Can Participate: Children ages 3 months to 12 years of age with cow’s milk allergy
Contact Information:
Deanna Hamilton | (919) 962-4405 | dhamito@email.unc.edu
For more information, click here

Systems Biology of Early Atopy (SUNBEAM)

Study Overview: We want to learn more about what factors put babies and toddlers at higher risk for developing food allergies and eczema. This is an observational research study, which means we will follow you and your child from birth to 3 years to learn more about how allergies develop.
Who Can Participate: Anyone who is 18 years or older, is currently pregnant, and is planning to deliver at UNC
Estimated Time Commitment: Approximately 3 years
Contact Information: Contact the study team at sunbeam@unc.edu
For more information, click here

  • A Multicenter, Open-Label, Long-Term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study  (ARC008) [more]
  • Regeneron: A Phase 2, Multicenter, Randomized, Double-blind-placebo-controlled study in pediatric subjects with peanut allergy to evaluate the efficacy and safety of Dupilumab and adjunct to peanut oral Immunotherapy (AR101-CODIT) [more]
  • EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX) [more]
  • A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin® Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study) [more]
  • Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) [more]
Interested in Participating in a Study?